|Bid||28.55 x 800|
|Ask||28.90 x 1800|
|Day's Range||28.38 - 28.80|
|52 Week Range||13.84 - 41.41|
|Beta (5Y Monthly)||143.89|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Common shares will be consolidated on the Nasdaq exchange where shareholders can continue trading under the symbol "PRTG" Westport, Connecticut--(Newsfile Corp. - April 16, 2021) - Portage Biotech Inc., (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical-stage immuno-oncology company focused on the development of therapies targeting cancer treatment resistance, today announced that it plans to voluntarily delist its common shares ("Shares") from the Canadian Securities Exchange (the "CSE"). Since Portage's Shares began trading ...
- Novel platform allows co-targeting of iNKT cells and tumor antigens in a single product- Trial marks the first milestone in a comprehensive clinical development plan to evaluate iNKT agonists to improve outcomes in a variety of solid tumors Westport, Connecticut--(Newsfile Corp. - April 8, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" ...
- The INVINCIBLE trial is a phase 2 study with a primary endpoint one month after starting treatment - Eight other phase 2 clinical data reads are expected from INT230-6 (PORT-1) over the next 24 monthsWestport, Connecticut--(Newsfile Corp. - March 25, 2021) - Portage Biotech Inc. (NASDAQ: PRTG) (CSE: PBT.U) ("Portage" or the "Company") a clinical stage immuno-oncology company accelerating research and development to overcome immune ...